Department of Gastroenterology and Hepatology, University Hospital Geneva, Geneva, Switzerland
AIDS. 2009 Sep 10;23(14):1918-22. doi: 10.1097/QAD.0b013e3283300a91.
Kaposi's sarcoma-associated herpesvirus (KSHV) specific T cell responses and KSHV viremia were analyzed in seven HIV-infected patients with active Kaposi's sarcoma lesions who initiated highly active antiretroviral therapy, and were compared between patients with improved Kaposi's sarcoma and those with progressive Kaposi's sarcoma requiring further systemic chemotherapy. Patients with controlled Kaposi's sarcoma disease demonstrated undetectable Kaposi's sarcoma viremia together with KSHV-specific CD8 T cells secreting interferon-gamma and tumor necrosis factor-alpha, whereas progressors showed increasing viremia with weak or no T-cell responses. These data point toward a potential role of KSHV-specific immunity in the control of AIDS-associated Kaposi's sarcoma.
卡波西肉瘤相关疱疹病毒 (KSHV) 特异性 T 细胞应答和 KSHV 病毒血症在 7 名开始接受高效抗逆转录病毒治疗的活动性卡波西肉瘤病变的 HIV 感染患者中进行了分析,并在卡波西肉瘤改善的患者和需要进一步全身化疗的进展性卡波西肉瘤患者之间进行了比较。控制良好的卡波西肉瘤患者的卡波西肉瘤病毒血症检测不到,并且 KSHV 特异性 CD8 T 细胞分泌干扰素-γ和肿瘤坏死因子-α,而进展患者则表现出病毒血症增加,T 细胞应答减弱或缺失。这些数据表明 KSHV 特异性免疫在控制 AIDS 相关卡波西肉瘤方面可能发挥作用。